Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density
Hend Smaoui, Lassaad Chtourou, Dana Jallouli, Samar Ben Jemaa, Iheb Karaa, Mouna Boudabbous, Manel Moalla, Hela Gdoura, Leila Mnif, Ali Amouri, Rim Akrout, Fatma Ayadi, Sofien Baklouti, Nabil Tahri- Biotechnology
Aim: Although Proton pump inhibitors (PPIs) are well-tolerated, their long-term use may be associated with decreased bone mass. Methods: This is a case-control study including patients treated with PPIs (>1 year) and control subjects who have not received PPIs treatment. Results: A total of 90 patients and 90 matched controls were included. PPIs use was associated with hypocalcemia and hypomagnesemia. Vitamin D3 deficiency and hyperparathyroidism were associated with PPIs use. Long-term PPIs use was significantly associated with decreased bone density. Risk factors of decreased bone mineral density (BMD) included age >50 years, menopause, lack of sun exposure, double PPIs dose, daily intake, post-meal intake and association with a mucoprotective agent. Conclusion: Our results highlight the risk of decreased BMD in patients on long-term PPIs treatment.